Prazosin Potentiates the Acute Hypotensive Effects of Nitroglycerin but Does Not Attenuate Nitrate Tolerance in Normal Conscious Rats

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 3, 2004, Pages 341-346

  Wang, Ellen Q ^a   Fung, Ho Leung ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Hemodynamics; Nitrate tolerance; Nitroglycerin; Prazosin; Sympathetic activation

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCERYL TRINITRATE; NITRATE; PRAZOSIN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SYMPATHETIC BLOCKING;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; DRUG SYNERGISM; DRUG TOLERANCE; HYPOTENSION; INJECTIONS, INTRAVENOUS; MALE; NITRATES; NITROGLYCERIN; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 1442276984     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200403000-00003     Document Type: Article

References (25)

1. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation. 2002;106:2404-2408.
2. Zanzinger J, Czachurski J, Seller H. Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide in vivo. Circ Res. 1994;75:1073-1077.
3. Hirai T, Musch TI, Morgan DA, et al. Differential sympathetic nerve responses to nitric oxide synthase inhibition in anesthetized rats. Am J Physiol. 1995;269:R807-R813.
4. Zanzinger J, Czachurski J, Seller H. Impaired modulation of sympathetic excitability by nitric oxide after long-term administration of organic nitrates in pigs. Circulation. 1998;97:2352-2358.
5. Schwarz P, Diem R, Dun NJ, et al. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res. 1995;77:841-848.
6. Zanzinger J, Czachurski J, Seller H. Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs. Circ Res. 1997;80:565-571.
7. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation. 1991;84:2336-2345.
8. Ma SX, Ignarro LJ, Byrns R, et al. Increased nitric oxide concentrations in posterior hypothalamus and central sympathetic function on nitrate tolerance following subcutaneous nitroglycerin. Nitric Oxide. 1999;3:153-161.
9. Wang EQ. Mechanistic Determinants of in vivo nitrate tolerance [Ph.D. thesis]. Buffalo: University at Buffalo; 2001.
10. Cohn JN. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation. 1990;82(suppl 2):159-167.
11. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41:233-243.
12. Wang EQ, Fung HL. Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats. AAPS Pharm Sci. 2002;4:E28.
13. Wang EQ, Lee WI, Brazeau D, et al. cDNA microarray analysis of vascular gene expression after nitric oxide donor infusions in rats: implications for nitrate tolerance mechanisms. AAPS Pharm Sci. 2002;4:E10.
14. Booth BP, Jacob S, Bauer JA, et al. Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol. 1996;28:432-438.
15. Yap PS, Fung HL. Pharmacokinetics of nitroglycerin in rats. J Pharm Sci. 1978;67:584-586.
16. Tseng C. Mechanisms of action of nitric oxide donors: A comparative study of nitroglycerin vs. S-nitroso-N-acetylpenicillamine [Ph.D. Thesis]. Buffalo: University at Buffalo; 1998.
17. Gori T, Floras JS, Parker JD. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol. 2002;40:2000-2005.
18. Pi X, Yan C, Kim D, et al. Differential expression of genes from nitrate-tolerant rat aorta. J Vasc Res. 2002;39:304-310.
19. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
20. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation. 2002;106:2510-2513.
21. Munzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res. 2000;86:E7-E12.
22. Wang EQ, Lee WI, Fung HL. Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. Br J Pharmacol. 2002;135:299-302.
23. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99:8306-8311.
24. Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annu Rev Pharmacol Toxicol. 2004;44 (in press).
25. Packer M. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol. 1990;16:932-935.